IBMT19101 / KTE-C19-104 / KITE Zuma 4 / Kristen O'DwyerResearch Question:
Is the drug KTE-X19 safe and effective in treating acute lymphoblastic leukemia (ALL)
or B-cell non-Hodgkin lymphoma (NHL)?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
The primary objectives of this study are to evaluate the safety and efficacy of brexucabtagene
autoleucel (KTE-X19) in pediatric and adolescent participants with relapsed/refractory
(r/r) B-precursor acute lymphoblastic leukemia (ALL) or relapsed or refractory (r/r)
B-cell non-Hodgkin lymphoma (NHL).
As of October 2022, no further patients with acute B-cell Acute Lymphoblastic Leukemia
(ALL) will be asked to join the study. The study remains open for recruitment for
patients that have B-cell Non Hodgkin Lymphoma (NHL).
Study Reference #: IBMT19101
Lead Researcher (Principal Investigator)
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search